Folgen
Marina Bacac
Marina Bacac
Bestätigte E-Mail-Adresse bei roche.com - Startseite
Titel
Zitiert von
Zitiert von
Jahr
An immune atlas of clear cell renal cell carcinoma
S Chevrier, JH Levine, VRT Zanotelli, K Silina, D Schulz, M Bacac, ...
Cell 169 (4), 736-749. e18, 2017
8812017
Metastatic cancer cell
M Bacac, I Stamenkovic
Annu. Rev. Pathol. Mech. Dis. 3, 221-247, 2008
4302008
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
S Herter, F Herting, O Mundigl, I Waldhauer, T Weinzierl, T Fauti, G Muth, ...
Molecular cancer therapeutics 12 (10), 2031-2042, 2013
3652013
Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors
DS Thommen, J Schreiner, P Müller, P Herzig, A Roller, A Belousov, ...
Cancer immunology research 3 (12), 1344-1355, 2015
3632015
A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors
M Bacac, T Fauti, J Sam, S Colombetti, T Weinzierl, D Ouaret, W Bodmer, ...
Clinical Cancer Research 22 (13), 3286-3297, 2016
3292016
Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment
A Seckinger, JA Delgado, S Moser, L Moreno, B Neuber, A Grab, S Lipp, ...
Cancer cell 31 (3), 396-410, 2017
2902017
Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial
M Hutchings, F Morschhauser, G Iacoboni, C Carlo-Stella, FC Offner, ...
Journal of Clinical Oncology 39 (18), 1959, 2021
2872021
Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and …
C Klein, I Waldhauer, VG Nicolini, A Freimoser-Grundschober, T Nayak, ...
Oncoimmunology 6 (3), e1277306, 2017
2272017
The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation
M Bacac, ACG Hotze, K van der Schilden, JG Haasnoot, S Pacor, ...
Journal of inorganic biochemistry 98 (2), 402-412, 2004
2152004
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy
C Claus, C Ferrara, W Xu, J Sam, S Lang, F Uhlenbrock, R Albrecht, ...
Science translational medicine 11 (496), eaav5989, 2019
2022019
Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity
S Herter, MC Birk, C Klein, C Gerdes, P Umana, M Bacac
The Journal of Immunology 192 (5), 2252-2260, 2014
1742014
CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies
M Bacac, S Colombetti, S Herter, J Sam, M Perro, S Chen, R Bianchi, ...
Clinical Cancer Research 24 (19), 4785-4797, 2018
1722018
Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer
A Planche, M Bacac, P Provero, C Fusco, M Delorenzi, JC Stehle, ...
PloS one 6 (5), e18640, 2011
1692011
A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents
S Herter, L Morra, R Schlenker, J Sulcova, L Fahrni, I Waldhauer, ...
Cancer Immunology, Immunotherapy 66, 129-140, 2017
1252017
Engineering therapeutic bispecific antibodies using CrossMab technology
C Klein, W Schaefer, JT Regula, C Dumontet, U Brinkmann, M Bacac, ...
Methods 154, 21-31, 2019
1232019
New cytotoxic and water-soluble bis (2-phenylazopyridine) ruthenium (II) complexes
ACG Hotze, M Bacac, AH Velders, BAJ Jansen, H Kooijman, AL Spek, ...
Journal of medicinal chemistry 46 (9), 1743-1750, 2003
1192003
CEA TCB: a novel head-to-tail 2: 1 T cell bispecific antibody for treatment of CEA-positive solid tumors
M Bacac, C Klein, P Umana
Oncoimmunology 5 (8), e1203498, 2016
1182016
Structure-dependent in vitro cytotoxicity of the isomeric complexes [Ru (L) 2 Cl 2](L= o-tolylazopyridine and 4-methyl-2-phenylazopyridine) in comparison to [Ru (azpy) 2 Cl 2]
ACG Hotze, SE Caspers, D de Vos, H Kooijman, AL Spek, A Flamigni, ...
JBIC Journal of Biological Inorganic Chemistry 9, 354-364, 2004
1112004
Intratumoral NAMI-A treatment triggers metastasis reduction, which correlates to CD44 regulation and tumor infiltrating lymphocyte recruitment
S Pacor, S Zorzet, M Cocchietto, M Bacac, M Vadori, C Turrin, B Gava, ...
Journal of Pharmacology and Experimental Therapeutics 310 (2), 737-744, 2004
1042004
Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leucocytes: implications for systemic use
S Pacor, A Giangaspero, M Bacac, G Sava, A Tossi
Journal of Antimicrobial Chemotherapy 50 (3), 339-348, 2002
972002
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20